Nurix Therapeutics Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.61%.
Did NRIX Beat Earnings? Q2 2025 Results
Nurix Therapeutics delivered a standout fiscal second quarter, with revenue of $44.06 million beating the $17.51 million consensus by 151.56% and a per-share loss of $0.52 coming in well ahead of the $0.74 estimate, representing a 30.15% positive surprise. The headline driver was collaboration activity, specifically $30.00 million in license revenue tied to two Sanofi license extensions, including the exercise of its option on the STAT6 program featuring degrader candidate NX-3911, alongside a $5.00 million clinical milestone from Gilead. Together, those payments helped push total revenue up 264.3% from $12.09 million in the year-ago quarter. Retail investor sentiment turned notably bullish following the report, with shares jumping on the results. Looking ahead, Nurix expects to initiate pivotal trials for lead asset bexobrutideg in relapsed/refractory CLL in the second half of calendar 2025, while a cash position of $485.80 million provides a firm financial foundation to advance its broader pipeline across oncology and autoimmune indications.
- $30 million in license revenue from two Sanofi license extensions during the quarter
- $5 million clinical milestone achieved under Gilead collaboration
- Accelerated enrollment and pivotal trial preparation for bexobrutideg driving increased R&D spending
“During our second quarter, Nurix delivered important collaboration milestones, resulting in Sanofi's extension of its license for our STAT6 program and FDA clearance of the IND for IRAK4 degrader GS-6791/NX-0479 in collaboration with Gilead.”
Nurix Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Nurix remains on track to initiate pivotal trials for bexobrutideg in CLL in the second half of calendar 2025. The company is expanding bexobrutideg into autoimmune indications with a new Phase 1b cohort for CLL patients with autoimmune hemolytic anemia and exploring the filing of a non-malignant hematology IND for autoimmune cytopenias in 2025. Clinical updates for zelebrudomide (NX-2127) and NX-1607 are anticipated in the second half of 2025. Cash, cash equivalents and marketable securities of $485.8 million (excluding $19 million in post-quarter milestone payments) are expected to fund ongoing development activities.
NRIX YoY Financials
NRIX Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.